CAS 98769-84-7|Reboxetine (mesylate)

Introduction：Basic information about CAS 98769-84-7|Reboxetine (mesylate), including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Reboxetine (mesylate) BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	Reboxetine (mesylate)
CAS Number	98769-84-7	Molecular Weight	409.496
Density	/	Boiling Point	443.7ºC at 760 mmHg
Molecular Formula	C₂₀H₂₇NO₆S	Melting Point	170-171ºC
MSDS	/	Flash Point	188.2ºC

Names

Name	Reboxetine mesylate
Synonym	More Synonyms

Reboxetine (mesylate) BiologicalActivity

Description	Reboxetine Mesylate is a norepinephrine reuptake inhibitor use in the treatment of unipolar depression.Target: OthersReboxetine is a drug of the norepinephrine reuptake inhibitor class. Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 μg/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the α2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively [1]. Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution [2]. Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex [3].
Related Catalog	Signaling Pathways >>Others >>OthersResearch Areas >>Neurological Disease
References	[1]. Wong, E.H., et al., Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry, 2000. 47(9): p. 818-29. [2]. Versiani, M., et al., Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry, 1999. 60(6): p. 400-6. [3]. Page, M.E. and I. Lucki, Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology, 2002. 27(2): p. 237-47.

Description

Reboxetine Mesylate is a norepinephrine reuptake inhibitor use in the treatment of unipolar depression.Target: OthersReboxetine is a drug of the norepinephrine reuptake inhibitor class. Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 μg/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the α2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively [1]. Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution [2]. Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex [3].

Related Catalog

Signaling Pathways >>Others >>OthersResearch Areas >>Neurological Disease

References

[1]. Wong, E.H., et al., Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry, 2000. 47(9): p. 818-29.

[2]. Versiani, M., et al., Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry, 1999. 60(6): p. 400-6.

[3]. Page, M.E. and I. Lucki, Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology, 2002. 27(2): p. 237-47.

Chemical & Physical Properties

Boiling Point	443.7ºC at 760 mmHg
Melting Point	170-171ºC
Molecular Formula	C₂₀H₂₇NO₆S
Molecular Weight	409.496
Flash Point	188.2ºC
Exact Mass	409.155914
PSA	102.47000
LogP	4.10740
InChIKey	CGTZMJIMMUNLQD-STYNFMPRSA-N
SMILES	CCOc1ccccc1OC(c1ccccc1)C1CNCCO1.CS(=O)(=O)O
Storage condition	2-8°C
Water Solubility	H2O: ~8 mg/mL at ≤60 °C

Safety Information

Safety Phrases	S22-S24/25
WGK Germany	3

Synonyms

Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (1:1)

REBOXETINE MESYLATE HYDRATE

REBOXETINE,MESYLATE

(2R)-rel-2-[(R)-(2-Ethoxyphenoxy)phenylmethyl]morpholine

EDRONAX

VESTRA

(2R)-2-[(R)-(2-Ethoxyphenoxy)(phenyl)methyl]morpholine methanesulfonate (1:1)

REBOXETINE, MESYLATE

Reboxetine (mesylate)

REBOXETINE MESILATE

Reboxetine hydrate mesylate

Reboxetinemesylate

(±)-(2R*)-2-[(aR*)-a-(o-Ethoxyphenoxy)benzyl]morpholine Methanesulfonate

RAC-N-BENZYL-N-[2-HYDROXYL-2-(4-BENZYLOXY-3-FORMAMIDOPHENYL)-ETHYL]-3-(4-METHOXYPHENYL)-2-PROPYLAMINE-D6

MFCD02184016

REBOXETIN MESYLATE

2-[(2-Ethoxyphenoxy)phenylmethyl]morpholine mesylate

Recommended......